Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nyxoah (NYXH)
NASDAQ:NYXH
Nyxoah (NYXH) Stock Price & Analysis
78 Followers
NYXH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.00 - $20.00
Previous Close$7.39
Volume24.44K
Average Volume (3M)40.54K
Market Cap
$274.27M
Enterprise Value$262.55M
Total Cash (Recent Filing)€21.61M
Total Debt (Recent Filing)€12.34M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Aug 06, 2024EPS Estimate
-$0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.63
Shares Outstanding28,660,000
10 Day Avg. Volume31,837
30 Day Avg. Volume40,539
Standard Deviation0.28
R-Squared0.08
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)2.32
Price to Sales (P/S)78.68
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$16.64Price Target Upside109.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Nyxoah News
PremiumCompany Announcements
Nyxoah Gains €37.5M Boost for OSA Innovations
PremiumCompany Announcements
Nyxoah Secures Major EIB Loan to Expand Operations
PremiumCompany Announcements
Nyxoah Edges Closer to US FDA Approval for Genio
Bulls Say, Bears Say
Bulls Say
Market OpportunityNyxoah estimates the target market for Genio in the U.S. is approximately 510,000 patients, representing an annual total addressable market in the U.S. of approximately $10 billion.
Regulatory MilestoneNyxoah announced that it has submitted the fourth and final module of its PMA application for Genio to the FDA.
Sales GrowthNyxoah reported 1Q24 Genio sales of €1.2M, compared to €0.4M in 1Q23 (177% growth YoY).
Bears Say
Capital RaiseAnalyst is lowering the price target to $18 from $22 due to dilution from the capital raise.
Market PenetrationThe European market will continue to be difficult to grow and penetrate.
Regulatory And Financial HurdlesHurdles ahead remain, including FDA approval, favorable CMS/commercial reimbursement, and additional financing and US sales force build/commercialization.
---
Ownership Overview
0.00%
Insiders
0.29% Mutual Funds
2.32% Other Institutional Investors
97.38% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
NYXH FAQ
What was Nyxoah’s price range in the past 12 months?
Nyxoah lowest stock price was $4.00 and its highest was $20.00 in the past 12 months.
What is Nyxoah’s market cap?
Currently, no data Available
When is Nyxoah’s upcoming earnings report date?
Nyxoah’s upcoming earnings report date is Aug 06, 2024 which is in 31 days.
How were Nyxoah’s earnings last quarter?
Nyxoah released its earnings results on May 14, 2024. The company reported -$0.449 earnings per share for the quarter, beating the consensus estimate of -$0.455 by $0.006.
Is Nyxoah overvalued?
According to Wall Street analysts Nyxoah’s price is currently Undervalued.
Does Nyxoah pay dividends?
Nyxoah does not currently pay dividends.
What is Nyxoah’s EPS estimate?
Nyxoah’s EPS estimate is -$0.46.
How many shares outstanding does Nyxoah have?
Nyxoah has 34,360,390 shares outstanding.
What happened to Nyxoah’s price movement after its last earnings report?
Nyxoah reported an EPS of -$0.449 in its last earnings report, beating expectations of -$0.455. Following the earnings report the stock price went up 7.203%.
Which hedge fund is a major shareholder of Nyxoah?
Among the largest hedge funds holding Nyxoah’s share is Iron Triangle Partners LP. It holds Nyxoah’s shares valued at 3M.
---
Nyxoah Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.64 (109.31% Upside)
$16.64 (109.31% Upside)
Blogger Sentiment
Bullish
NYXH Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 78.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 7.0%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.76%
12-Months-Change
Fundamentals
Return on Equity
-40.68%
Trailing 12-Months
Asset Growth
-25.58%
Trailing 12-Months
Company Description
Nyxoah
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
---
NYXH Earnings Call
Q1 2024
0:00 / 0:00
---
NYXH Stock 12 Month Forecast
Average Price Target
$16.64
▲(109.31% Upside)
Technical Analysis
Best Analysts Covering NYXH
1 Year
1 Year Success Rate
5/10 ratings generated profit
1 Year Average Return
+5.04%
reiterated a buy rating 6 days ago
Copying Edward White's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +5.04% per trade.
---